CCMU
LRMR icon

Cheyne Capital Management (UK)’s Larimar Therapeutics LRMR Stock Holding History

Cheyne Capital Management (UK)’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-63,680
Closed -$263K – 37
2022
Q4 		$263K Buy
+63,680
New +$217K 0.46% 51

Other funds holding LRMR

Deerfield Management
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Woodline Partners
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return

Cheyne Capital Management (UK)'s LRMR Position: Q1 2023 in Review

Cheyne Capital Management (UK) sold out of Larimar Therapeutics (LRMR) in Q1 2023, closing a stake of 63,680 shares — an estimated $263K sold.

Cheyne Capital Management (UK) first reported a position in LRMR in Q4 2022 and held it in 1 quarter. The position peaked at $263K in Q4 2022. 68 funds tracked by Wall St. Rank hold LRMR as of Q1 2023.

  • Cheyne Capital Management (UK) reported no remaining Larimar Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Cheyne Capital Management (UK) sold 63,680 Larimar Therapeutics shares in Q1 2023, an estimated $263K.
  • Cheyne Capital Management (UK) first reported a position in Larimar Therapeutics in Q4 2022 and held it in 1 quarter.
  • Cheyne Capital Management (UK)'s Larimar Therapeutics position peaked at $263K in Q4 2022.
  • 68 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q1 2023.

Based on Cheyne Capital Management (UK)'s 13F filing for Q1 2023, filed 3 May 2023.